According to the Financial Times, the 23 analysts offering 12-month price targets for GlaxoSmithKline Plc have a median target of GBX1 530, with a high estimate of GBX1 758 and a low estimate of GBX1 250.
GlaxoSmithKline plc logo GlaxoSmithKline plc (LON:GSK) has earned a consensus recommendation of �Hold� from the twenty-four ratings firms that are currently covering the stock, American Banking and Market News reports.
GlaxoSmithKline Plc (GSK)'s Ebola vaccine produced responses from the immune system and didn't raise safety concerns in a study with 20 healthy adults, completing an initial step toward making it widely available.
Receive News & Ratings for GlaxoSmithKline plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline plc and related companies with Analyst Ratings Network's FREE daily ...
Investor-Edge has initiated coverage on the following equities: GlaxoSmithKline PLC (NYSE: GSK), Bristol-Myers Squibb Company (NYSE: BMY), Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Endo International PLC (NASDAQ: ENDP), and Allergan Inc.